Boston Scientific (BSX) Receives FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
More News related to ABT
- Abbott Labs (ABT) to Streamline Operations; Sees $370 Million in Pre-Tax Charges
- Patient Side Point-of-Care Testing in the Emergency Department Enables Quicker Treatment Decisions for Patients With Chest Pain
- Absolute's Computrace LoJack for Laptops Now Available at Future Shop
- Veteran High-Tech Executive Appointed COO of Absolute Software
- Gates' The Bill and Melinda Gates Foundation Shows New Positions in Crocs (CROX), Dick's (DKS) and Raised Stakes in McDonald's (MCD), FedEx (FDX) and AIG (AIG)
More News related to BSX
- Paulson's 13F Shows New Stakes In BAC, LNG, WHQ; Raised Stakes in BSX and Others
- Notable Analyst Rating Changes 7/25: DAL, GOOG, CSIQ, JNPR Upgraded; SIRI, SSP, ANF Downgraded
- Piper Jaffray Initiates Boston Scientific (BSX) with a Buy
- Pre-Open Movers 7/22: Assured Guaranty (AGO) Sinks On Possible Moody's Downgrade, Foundry Networks (FDRY) Up on Buyout
- After-Hours Movers 7/21: Apple (AAPL), American Exp (AXP), Texas Inst (TXN), SanDisk (SNDK) Sink on Results
More News related to FDA
- Biogen Idec (BIIB) Initiates Phase III Clinical Trial for ADENTRI(R)
- Telik's (TELK) Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
- Telik's (TELK) Proteasome Inhibitor Program Meets a Preclinical Development Milestone
- FDA Says It Is Investigating Potential Link Between Vytorin and Risk of Cancer (MRK, SGP)
- AMAG Pharmaceuticals (AMG) Receives Fast Track Designation from FDA for Vascular-Enhanced Magnetic Resonance Imaging
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. FDA has approved the PROMUS(TM) Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.
The PROMUS Stent is a private-labeled XIENCE(TM) V Everolimus-Eluting Coronary Stent System manufactured by Abbott Labs (NYSE: ABT) and distributed by Boston Scientific. FDA approval clears the way for Boston Scientific to launch the PROMUS Stent immediately in the U.S.
The PROMUS Stent expands Boston Scientific's drug-eluting stent portfolio, which includes the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System and the TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System, making Boston Scientific the only company to offer physicians the choice of two distinct drugs on separate DES platforms.
Boston Scientific Corporation engages in the development, manufacture, and marketing of medical devices that are used in various interventional medical specialties worldwide.
Related Categories
FDAStocks Mentioned
-0.30
+0.24Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Congrats to BSX
Kevin Ott on Jul 2, 2008 05:46 PMThis is great news for the DES market. BSX will be the first and only for the seeable future to have two distinct platforms to finally give doctors a choice. After much debate for several years, finally a company can offer a choice without having to pressure physicians to only their product. Even though ABT also has the product under the name Xience, they still do not have the ability to offer choice. Both products have demonstrated effectiveness and BSX has a real stake in the landscape.